ANCA Associated Vasculitis Clinical Trial
— LEFAZAREMOfficial title:
The Efficacy of Leflunomide for the Maintenance Therapy of ANCA Associated Vasculitis
This study is a prospective, open-labelled, randomized, controlled,multi-center clincial trial. The aim of this study is to verify that the remission rate of patients treated with Leflunomide is not inferior to that of patients treated with Azathioprine.
Status | Recruiting |
Enrollment | 114 |
Est. completion date | December 31, 2024 |
Est. primary completion date | November 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Patients age 18 to 75 years, both genders can be included. 2. Patients who are newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiitis, or EGPA in complete remission after combined treatment with glucocorticoids and pulse cyclophosphamide or Rituximab. Remission is defined as a Birmingham Vasculitis Activity Score(BVAS version 3) of 0. 3. Patients must fulfill the 1990 ACR classification criteria of GPA, EGPA and 2012 modified Chapel Hill classification criteria of MPA. 4. Patients have to be ANCA-positive at diagnosis or during the course of their disease. 5. Patients must sign the informed consent. Exclusion Criteria: 1. Patients with TPMT gene mutation; 2. Patients who had been treated with either AZA or LEF but relapsed in the past; 3. Patients who had been treated with either AZA or LEF but had to stop due to adverse events or intolerance; 4. Patients who have planned for pregnancy in next 2 years; 5. Patients with severe liver dysfunction(defined as the elevation of liver enzyme 3 times the upper limit or Child grade III) or ESRD; 6. Patients with uncontrolled sever hypertension, diabetes, active bacteria or fungal infection; 7. Patients with active hepatitis virus infection as well as patients who have active mycobacteria infection; 8. Patients who are not eligible according to the judge of the principal investigators or site investigators. |
Country | Name | City | State |
---|---|---|---|
China | Peking Union Medical College Hospital | Beijing | |
China | AnHui provincial hospital | Hefei | Anhui |
China | the Affiliated Hospital of Inner Mongolia Medical University | Hohhot | Inner Mongolia |
China | the Affiliated Hospital of Kunming Medical University | Kunming | Yunnan |
Lead Sponsor | Collaborator |
---|---|
Chinese SLE Treatment And Research Group | Affiliated Hospital of Jilin University, Changchun,China, Beijing Shijitan Hospital, Capital Medical University, Second Affiliated Hospital of Nanchang University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai Zhongshan Hospital, Sichuan Province People's Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of Kunming Medical College |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the percentage of patients with major relapse in 18 months follow-up time | the percentage of patients with major relapse (re-appearance or worsening of disease with a BVAS >0 and involvement of at least one major organ, a life-threatening manifestation, or both) at month 18 | from inclusion to the end of the study, 18 months in total | |
Secondary | The rate of minor relapse of the AZA and LEF treatment group in 18 months. | The rate of minor relapse (reappearance or worsening of disease with a BVAS >0, not corresponding to a major relapse but requiring mild treatment intensification) of the AZA and LEF treatment group. | from inclusion to the end of the study, 18 months in total | |
Secondary | The rate of adverse events and their severity in both LEF and AZA treated patients during 18 months of the study period. | 2. The rate of adverse events and their severity(Severe events were defined as the adverse events of grade 3 or 4, deaths caused by any cause, cancers, side effects that necessitate hospitalization) in both LEF and AZA treated patients during the study period. | from inclusion to the end of the study, 18 months in total | |
Secondary | Patients progress to ESRD at the end of the study | Patients progress to ESRD at the end of the study | from inclusion to the end of the study, 18 months in total |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06462768 -
Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
|
||
Recruiting |
NCT03942887 -
Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
|
Phase 3 | |
Not yet recruiting |
NCT06420154 -
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
|
Early Phase 1 | |
Completed |
NCT04895878 -
Patients With Co-occurrence of ANCA Vasculitis and Sjögren Syndrome
|
||
Completed |
NCT00293072 -
Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis
|
Phase 2 | |
Recruiting |
NCT04664465 -
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
|
||
Recruiting |
NCT05315141 -
Multicenter Cohort Study of AAV in Hunan of China
|
||
Terminated |
NCT05376319 -
PR3-AAV Resilient Remission or PRRR
|
Phase 2 | |
Recruiting |
NCT05962840 -
Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
|
Phase 4 | |
Suspended |
NCT03906227 -
Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis
|
N/A | |
Not yet recruiting |
NCT06152172 -
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
|
Phase 1 | |
Not yet recruiting |
NCT05946564 -
A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
|
Phase 3 | |
Recruiting |
NCT04923074 -
the Application of Diffusion Tensor Imaging in the Evaluation of Peripheral Neuropathy in ANCA Associated Vasculitis
|
||
Active, not recruiting |
NCT01633476 -
CMV Modulation of the Immune System in ANCA-associated Vasculitis
|
Phase 2 | |
Not yet recruiting |
NCT05416723 -
Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P)
|
||
Recruiting |
NCT06277427 -
Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
|
N/A | |
Active, not recruiting |
NCT03967925 -
Rituximab and Belimumab Combination Therapy in PR3 Vasculitis
|
Phase 2 | |
Recruiting |
NCT05630612 -
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
|
Phase 2 | |
Recruiting |
NCT04316494 -
Hydroxychloroquine in ANCA Vasculitis Evaluation
|
Phase 4 | |
Recruiting |
NCT03698071 -
Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
|
N/A |